Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study

PURPOSE: Recent clinical trials have demonstrated that zoledronic acid (ZOL) significantly prolongs survival in prostate cancer patients undergoing androgen deprivation therapy. This pilot study investigated the influence of ZOL on circulating tumor cell (CTC) counts in prostate cancer patients in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Hisamitsu, Lu, Yan, Tanaka, Toshiaki, Wakumoto, Yoshiaki, Kitamura, Kosuke, Muto, Satoru, Yamaguchi, Raizo, Masumori, Naoya, Horie, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society (APPS) 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186959/
https://www.ncbi.nlm.nih.gov/pubmed/25325027
http://dx.doi.org/10.12954/PI.14056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186959/
https://www.ncbi.nlm.nih.gov/pubmed/25325027
http://dx.doi.org/10.12954/PI.14056

Ejemplares similares